Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of Schizophrenia with ergot derivatives.

Literature DB >> 119270

Treatment of Schizophrenia with ergot derivatives.

Abstract

Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1979 PMID： 119270 DOI： 10.1007/bf00428312

Source DB: PubMed Journal: Psychopharmacology (Berl) ISSN： 0033-3158 Impact factor: 4.530

20 in total

Review 1. Developments in the pharmacology and therapeutics of parkinsonism.

Authors: D B Calne
Journal: Ann Neurol Date: 1977-02 Impact factor: 10.422

2. Pre- and postsynaptic action of bromocriptine: its pharmacological effects on shcizophrenia and neurological diseases.

Authors: M Trabucchi; V M Andreoli; L Frattola; P F Spano
Journal: Adv Biochem Psychopharmacol Date: 1977

3. Effects of bromocriptine on central dopaminergic receptors.

Authors: M Trabucchi; P F Spano; G C Tonon; L Frattola
Journal: Life Sci Date: 1976-07-15 Impact factor: 5.037

Review 4. Endocrine profile of ergot alkaloids.

Authors: E E Můller; A E Panerai; D Cocchi; P Mantegazza
Journal: Life Sci Date: 1977-12-01 Impact factor: 5.037

5. Bromocriptine, dihydroergotoxine, methysergide, d-LSD, CF25--397, and 29--712: effects on the metabolism of the biogenic amines in the brain of the rat.

Authors: H R Bürki; H Asper; W Ruch; P E Züger
Journal: Psychopharmacology (Berl) Date: 1978-05-31 Impact factor: 4.530

6. Lergotrile and lisuride: in vivo dopaminergic agonists which do not stimulate the presynaptic dopamine autoreceptor.

Authors: J W Kebabian; P R Kebabian
Journal: Life Sci Date: 1978-11-27 Impact factor: 5.037

7. Selective labeling of pre-synaptic receptors by 3H-dopamine, 3H-apomorphine and 3H-clonidine; labeling of post-synaptic sites by 3H-neuroleptics.

Authors: M Titeler; J L Tedesco; P Seeman
Journal: Life Sci Date: 1978-08-14 Impact factor: 5.037

Review 8. Multiple classes of dopamine receptors in mammalian central nervous system: the involvement of dopamine-sensitive adenylyl cyclase.

Authors: J W Kebabian
Journal: Life Sci Date: 1978-08-07 Impact factor: 5.037

Treatment of Schizophrenia with ergot derivatives.

Review 1. Developments in the pharmacology and therapeutics of parkinsonism.

2. Pre- and postsynaptic action of bromocriptine: its pharmacological effects on shcizophrenia and neurological diseases.

3. Effects of bromocriptine on central dopaminergic receptors.

Review 4. Endocrine profile of ergot alkaloids.

5. Bromocriptine, dihydroergotoxine, methysergide, d-LSD, CF25--397, and 29--712: effects on the metabolism of the biogenic amines in the brain of the rat.

6. Lergotrile and lisuride: in vivo dopaminergic agonists which do not stimulate the presynaptic dopamine autoreceptor.

7. Selective labeling of pre-synaptic receptors by 3H-dopamine, 3H-apomorphine and 3H-clonidine; labeling of post-synaptic sites by 3H-neuroleptics.

Review 8. Multiple classes of dopamine receptors in mammalian central nervous system: the involvement of dopamine-sensitive adenylyl cyclase.

9. Schizophrenic symptoms improve with apomorphine.

10. Experiences with a new ergoline (CF 25-397) in parkinsonism.

1. Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy.

2. Binding of antiparkinsonian ergot derivatives to the dopamine receptor.